MiddleBrook Pharmaceuticals, Inc. to Present at Lehman Brothers Global Healthcare Conference

GERMANTOWN, Md., March 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that Dr. Edward M. Rudnic, MiddleBrook president and CEO, will deliver a corporate presentation on Tuesday, March 18, 2008, at 4:45 p.m. Eastern Time.

The presentation will take place as part of the Lehman Brothers Eleventh Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida. Dr. Rudnic's remarks will be available live on the MiddleBrook web site, where they also will be archived for 30 days.

To access the presentation, log on to http://www.middlebrookpharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

CONTACT: Robert Bannon, Vice President, Investor Relations & Corporate
Communications of MiddleBrook Pharmaceuticals, Inc., +1-301-944-6710,
rbannon@middlebrookpharma.com

Web site: http://www.middlebrookpharma.com/

MORE ON THIS TOPIC